抑郁症和中风发病率和死亡率的风险:元分析和系统审查
An Pan1, Qi Sun, Olivia I Okereke
1Department of Nutrition, Harvard School of Public Health, 655 Huntington Ave, Boston, MA 02115, USA.
JAMA
|September 22, 2011
概括
抑郁症显著增加了中风的风险,包括致命和缺血性类型. 这一元分析证实了抑郁症与中风发病率和死亡率较高之间存在一致的联系.
科学领域:
- 神经学 神经学
- 精神病学是一种精神病学.
- 流行病学 流行病学
背景情况:
- 现有的研究表明,抑郁症与中风风险增加之间存在联系,但研究结果不一致.
- 抑郁症是一种普遍存在的心理健康状况,具有重大公共健康影响.
研究的目的:
- 对成年人抑郁症和中风风险之间的关联进行系统审查和元分析前性研究.
- 提供综合评估证据,将抑郁症与中风发病率和死亡率联系起来.
主要方法:
- 搜索了MEDLINE,EMBASE和PsycINFO数据库,并通过手动搜索进行了补充.
- 包括28项前性队列研究,包括317,540名参与者和8478例中风病例.
- 使用固定效应或随机效应模型汇总调整后的危险比率 (HRs);评估出版偏差.
主要成果:
- 综合调整后的HR值为1.45 (95% CI,1.29-1.63) 在全中风中观察到.
- 发现致命性中风 (HR=1.55) 和缺血性中风 (HR=1.25) 的风险增加.
- 绝对风险差异表明,由于抑郁症,每年每10万个人增加106例中风病例.
结论:
- 抑郁症与中风发病率和死亡率的风险增加有关.
- 这些发现强调了在中风预防策略中解决抑郁症的重要性.
更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.0K
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.3K
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Actuarial Approach
384
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
384
Kaplan-Meier Approach
792
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
792
Comparing the Survival Analysis of Two or More Groups
712
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
712
Hazard Rate
525
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
525
Hazard Ratio
756
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
756
